Volume 23 Issue 12
Dec.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(12): 2054-2058
FANG Xiaojing, HOU Yanyan, GUO Suyang. Clinicopathological and prognostic significance of CDK16 in patients with intrauterine membrane carcinoma[J]. Chinese Journal of General Practice, 2025, 23(12): 2054-2058. doi: 10.16766/j.cnki.issn.1674-4152.004290
Citation: FANG Xiaojing, HOU Yanyan, GUO Suyang. Clinicopathological and prognostic significance of CDK16 in patients with intrauterine membrane carcinoma[J]. Chinese Journal of General Practice, 2025, 23(12): 2054-2058. doi: 10.16766/j.cnki.issn.1674-4152.004290
shu

Clinicopathological and prognostic significance of CDK16 in patients with intrauterine membrane carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.004290

  • Department of Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 2023AH052012

  • Received Date: 2024-10-23
    Available Online: 2026-03-13
    Abstract
  •   Objective  To investigate the clinicopathological and prognostic significance of CDK16 expression in intrauterine carcinoma (EC), and to provide an evaluation index for the prognosis of EC.  Methods  A retrospective study was conducted on 96 patients with endometrial cancer who were diagnosed and underwent curative surgery at the First Affiliated Hospital of Bengbu Medical University between February 2019 and December 2022, along with 15 normal endometrial tissue block specimens from the same period. Clinicopathological information was collected and the expression of CDK16 protein was detected by immunohistochemistry. The relationship between the different expression levels of CDK16 and the clinicopathological parameters and prognosis of patients with intrauterine membrane carcinoma were explored.  Results  The high expression rates of CDK16 in normal endometrial tissues and endometrial cancer tissues were 20.0% (3/15) and 67.7% (65/96), respectively. The high expression rate of CDK16 in endometrial cancer tissues was significantly higher than that in normal endometrial tissues (P < 0.05). The high expression rates of CDK16 in FIGO stage Ⅰ/Ⅱ and FIGO stage Ⅲ patients were 61.0% (47/77) and 94.8% (18/19), respectively. The high expression rates of CDK16 in patients without lymph node metastasis and those with lymph node metastasis were 65.9% (58/88) and 87.5% (7/8), respectively. The high expression rate of CDK16 in patients without vascular invasion was lower than that in patients with vascular invasion (P < 0.05). Multivariate Cox proportional hazards model results showed that FIGO stage, lymph node metastasis, CDK16 expression intensity were influencing factors of pro-gression-free survival (PFS) and overall survival (OS), P < 0.05.  Conclusion  The expression of CDK16 is enhanced in intrauterine carcinoma. CDK16 is a potential prognostic marker for intrauterine carcinoma.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    陈晓军, 张剑峰, 陆雯, 等. 子宫内膜癌手术治疗质量控制与评价标准中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(6): 626-637.

    CHEN X J, ZHANG J F, LU W, et al. Chinese expert consensus on quality control and evaluation standards for surgical treatment of endometrial cancer (2024 edition)[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2024, 40(6): 626-637.
    [2]
    颜舜轩, 黄涛, 黄佳佳, 等. 子宫内膜癌MKI67表达与预后的相关性[J]. 医药论坛杂志, 2024, 45(15): 1578-1585.

    YAN S X, HUANG T, HUANG J J, et al. The correlation between MKI67 expression in endometrial cancer and prognosis[J]. Journal of Medical Forum, 2024, 45(15): 1578-1585.
    [3]
    张岩, 江路, 燕鑫. 子宫内膜癌免疫检查点阻断治疗的进展[J]. 中国医刊, 2021, 56(8): 833-836.

    ZHANG Y, JIANG L, YAN X. Progress in immune checkpoint blockade therapy for endometrial cancer[J]. Chinese Journal of Medicine, 2021, 56(8): 833-836.
    [4]
    洪小惠. 子宫内膜癌中ER、PR、P53、Ki-67及Vimentin的表达及临床意义[D]. 福州: 福建医科大学, 2021.

    HONG X H. The expression of ER, PR, P53, Ki-67 and Vimentin in endometrial carcinoma and its clinical significance[D]. Fuzhou: Fujian Medical University, 2021.
    [5]
    GU X H, SHEN H H, BAI W Q, et al. Endometrial cancer prognosis prediction using correlation models based on CDK family genes[J]. Front Genet, 2022, 13: 1021600. DOI: 10.3389/fgene.2022.1021600.
    [6]
    邵卓伟, 吴仕波. CDK16在人类癌症中的作用与机制[J]. 生命的化学, 2024, 44(2): 233-242.

    SHAO Z W, WU S B. The role and mechanism of CDK16 in human cancer[J]. Chemical Life, 2024, 44(2): 233-242.
    [7]
    WANG X, LIU R Q, LI S, et al. The roles, molecular interactions, and therapeutic value of CDK16 in human cancers[J]. Biomed Pharmacother, 2023, 164: 114929. DOI: 10.1016/j.biopha.2023.114929.
    [8]
    杨垲威, 唐开, 廖霞, 等. 基于生物信息学研究CDK1在ACC中的表达及临床意义[J]. 医学理论与实践, 2024, 37(16): 2701-2705, 2727.

    YANG K W, TANG K, LIAO X, et al. Expression of CDK1 in ACC and its clinical significance based on bioinformatics research[J]. Medical Theory and Practice, 2024, 37(16): 2701-2705, 2727.
    [9]
    郭勤浩, 余敏, 吴小华. 2022年度妇科肿瘤诊治进展[J]. 中国癌症杂志, 2023, 33(1): 14-24.

    GUO Q H, YU M, WU X H. Progress in diagnosis and treatment of gynecological tumors in 2022[J]. Chinese Journal of Cancer, 2023, 33(1): 14-24.
    [10]
    沈晓瑜, 贾岳, 杨志芹, 等. 子宫内膜癌流行病学趋势及危险因素的研究进展[J]. 华南预防医学, 2022, 48(9): 1079-1081, 1086.

    SHEN X Y, JIA Y, YANG Z Q, et al. Epidemic disease and risk factors of endometrial cancer[J]. Huanan Preventive Medicine, 2022, 48(9): 1079-1081, 1086.
    [11]
    张心, 王建东. 子宫内膜癌相关流行病学高危因素的研究进展[J]. 医学综述, 2021, 27(15): 2995-2999.

    ZHANG X, WANG J D. Research progress on epidemiological risk factors related to endometrial cancer[J]. Medical Recapitulate, 2021, 27(15): 2995-2999.
    [12]
    邢莹, 余姝婷, 朱小利. LncRNA XIST在子宫内膜癌组织中的表达及其靶向microRNA-101-3p对癌细胞生物行为学的影响[J]. 中国现代医学杂志, 2022, 32(21): 24-30.

    XING Y, YU S T, ZHU X L. Expression of LncRNA XIST in endometrial cancer tissues and its targeting of microRNA-101-3p on the biological behavior of cancer cells[J]. Chinese Journal of Modern Medicine, 2022, 32(21): 24-30.
    [13]
    王莹, 夏潇, 韩恩善. 子宫内膜癌中Ki-67及COL17A1表达水平与临床病理及预后关系[J]. 宁夏医学杂志, 2024, 46(8): 705-708.

    WANG Y, XIA X, HAN E S. Expression levels of Ki-67 and COL17A1 in endometrial cancer and their relationship with clinicopathology and prognosis[J]. Ningxia Medical Journal, 2024, 46(8): 705-708.
    [14]
    谷保双, 赵彩琴, 徐方方. 肥胖、高血糖和高脂血症与子宫内膜癌患者临床特征的关系[J]. 新乡医学院学报, 2025, 42(2): 133-137, 142.

    GU B S, ZHAO C Q, XU F F. The relationship of obesity, hyperglycemia, and hyperlipidemia with clinical characteristics in patients with endometrial cancer[J]. Journal of Xinxiang Medical University, 2025, 42(2): 133-137, 142.
    [15]
    沈晓瑜, 贾岳, 杨志芹, 等. 子宫内膜癌流行病学趋势及危险因素的研究进展[J]. 华南预防医学, 2022, 48(9): 1079-1081, 1086.

    SHEN X Y, JIA Y, YANG Z Q, et al. Research progress on epidemiological trends and risk factors of endometrial cancer[J]. South China Journal of Preventive Medicine, 2022, 48(9): 1079-1081, 1086.
    [16]
    吴倩华, 李碧岚. 子宫内膜癌免疫治疗的进展及现状[J]. 现代妇产科进展, 2022, 31(5): 389-393.

    WU Q H, LI B L. Progress and current status of immunotherapy for endometrial cancer[J]. Progress in Obstetrics and Gynecology, 2022, 31(5): 389-393.
    [17]
    刘逸贤, 陈嵘, 程忠平. 免疫治疗在晚期或复发性子宫内膜癌中的应用进展[J]. 中华全科医学, 2023, 21(10): 1753-1756, 1797. doi: 10.16766/j.cnki.issn.1674-4152.003217

    LIU Y X, CHEN R, CHENG Z P. Advances in the application of immunotherapy for advanced or recurrent endometrial cancer[J]. Chinese Journal of General Practice, 2023, 21(10): 1753-1756, 1797. doi: 10.16766/j.cnki.issn.1674-4152.003217
    [18]
    顾园, 李平, 李晶. CDK14和FOLR1在结肠癌组织中的表达及与患者临床病理特征和预后的关系[J]. 国际消化病杂志, 2024, 44(2): 88-93.

    GU Y, LI P, LI J. Expression of CDK14 and FOLR1 in colon cancer tissues and their relationship with clinicopathological features and prognosis[J]. International Journal of Digestive Diseases, 2024, 44(2): 88-93.
    [19]
    YANG Q, YU H, LI Q. Genome-Wide analysis of the cyclin-dependent kinases (CDK) and cyclin family in molluscs[J]. Journal of Ocean University of China, 2021, 20(6): 1469-1482. doi: 10.1007/s11802-021-4758-4
    [20]
    翟欣影, 王丽华, 李艳华. PD-1、PD-L1在铂耐药卵巢上皮性癌组织中的表达及其临床意义[J]. 中华全科医学, 2024, 22(6): 966-970. doi: 10.16766/j.cnki.issn.1674-4152.003545

    ZHAI X Y, WANG L H, LI Y H. Expression of PD-1 and PD-L1 in platinum-resistant epithelial ovarian cancer tissues and their clinical significance[J]. Chinese Journal of General Practice, 2024, 22(6): 966-970. doi: 10.16766/j.cnki.issn.1674-4152.003545
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (11) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return